{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:35Z","timestamp":1786119275384,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/mbc.0b013e32834740ba","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T03:04:13Z","timestamp":1304391853000},"page":"512-520","source":"Crossref","is-referenced-by-count":1,"title":["Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus"],"prefix":"10.1097","volume":"22","author":[{"given":"Nazri","family":"Mustaffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhairi","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Zaidah","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurkurnai","family":"Yusof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-11-20210203","first-page":"2","article-title":"The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies.","volume":"18","author":"Ramlo-Halsted","year":"2000","journal-title":"Clin Diab"},{"key":"R3-11-20210203","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.CIR.0000025403.20953.23","article-title":"Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.","volume":"106","author":"Haffner","year":"2002","journal-title":"Circulation"},{"issue":"Suppl 2","key":"R4-11-20210203","first-page":"A68","article-title":"Rosiglitazone improves vascular reactivity oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect.","volume":"50","author":"Mohanty","year":"2001","journal-title":"Diabetes"},{"key":"R5-11-20210203","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.101.11.1311","article-title":"Expression and function of PPAR in rat and human vascular smooth muscle cells.","volume":"101","author":"Law","year":"2000","journal-title":"Circulation"},{"key":"R7-11-20210203","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/diacare.26.1.172","article-title":"Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.","volume":"26","author":"Raji","year":"2003","journal-title":"Diab Care"},{"key":"R8-11-20210203","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMcibr1012075","article-title":"Rosiglitazone PPAR and type 2 diabetes.","volume":"363","author":"Kahn","year":"2010","journal-title":"N Engl J Med"},{"key":"R10-11-20210203","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Drug therapy: thiazolidinediones.","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"R11-11-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0049-3848(96)00222-8","article-title":"Endothelial markers in diabetes mellitus.","volume":"85","author":"Galajda","year":"1997","journal-title":"Thromb Res"},{"key":"R12-11-20210203","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1210\/jcem.83.5.4932","article-title":"Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes.","volume":"83","author":"Minamikawa","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-11-20210203","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(00)00895-0","article-title":"Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with noninsulin dependent diabetes mellitus: a serial intravascular ultrasound study.","volume":"36","author":"Takagi","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R14-11-20210203","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1161\/01.ATV.0000124890.40436.77","article-title":"Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.","volume":"24","author":"Sidhu","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R15-11-20210203","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2337\/diacare.27.11.2654","article-title":"Preventive effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.","volume":"27","author":"Choi","year":"2004","journal-title":"Diab Care"},{"key":"R16-11-20210203","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMp1011042","article-title":"Jackevicius. Responding to an FDA warning: geographic variation in the use of rosiglitazone.","volume":"363","author":"Shah","year":"2010","journal-title":"N Engl J Med"},{"key":"R17-11-20210203","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.amjcard.2005.07.041","article-title":"Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death).","volume":"96","author":"Beckman","year":"2005","journal-title":"Am J Cardiol"},{"key":"R18-11-20210203","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/01.CIR.0000129501.88485.1f","article-title":"Endothelial function: a critical determinant in atherosclerosis C","volume":"109","author":"Landmesser","year":"2004","journal-title":"irculation"},{"key":"R19-11-20210203","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2003.04.001","article-title":"The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.","volume":"42","author":"Sidhu","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R20-11-20210203","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/s-2002-36772","article-title":"The ankle-brachial blood pressure index as a risk indicator of generalised atherosclerosis.","volume":"2","author":"Spacil","year":"2002","journal-title":"Semin Vasc Med"},{"key":"R21-11-20210203","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/01.ATV.0000168911.78624.b7","article-title":"Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review.","volume":"25","author":"Doobay","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R22-11-20210203","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM200105243442108","article-title":"Drug therapy: medical treatment of peripheral arterial disease and claudication.","volume":"344","author":"Hiatt","year":"2001","journal-title":"N Engl J Med"},{"key":"R23-11-20210203","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.313.7070.1440","article-title":"Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study.","volume":"313","author":"Leng","year":"1996","journal-title":"BMJ"},{"key":"R24-11-20210203","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5694\/j.1326-5377.2004.tb06206.x","article-title":"Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications.","volume":"181","author":"Norman","year":"2004","journal-title":"Med J Aust"},{"key":"R25-11-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/aje\/kwi167","article-title":"Ankle-brachial index and subclinical cardiac and carotid disease: The Multi-Ethnic Study of Atherosclerosis.","volume":"162","author":"McDermott","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"Suppl 1","key":"R26-11-20210203","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1002\/1520-7560(200009\/10)16:1+<::AID-DMRR113>3.0.CO;2-S","article-title":"International consensus and practical guidelines on the management and the prevention of the diabetic foot: International Working Group on the Diabetic Foot.","volume":"16","author":"Apelqvist","year":"2000","journal-title":"Diabetes Metab Res Rev"},{"key":"R28-11-20210203","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/1389450033490920","article-title":"Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions.","volume":"4","author":"Garg","year":"2003","journal-title":"Curr Drug Targets"},{"issue":"Suppl","key":"R29-11-20210203","doi-asserted-by":"crossref","first-page":"18J","DOI":"10.1016\/S0002-9149(03)00612-X","article-title":"Insulin resistance, inflammation, and the prediabetic state.","volume":"92","author":"Haffner","year":"2003","journal-title":"Am J Cardiol"},{"key":"R30-11-20210203","first-page":"635","article-title":"Misoprostol as agonist of IP2 receptor.","volume":"53","author":"Goszcz","year":"2002","journal-title":"J Physiol Pharmacol"},{"key":"R31-11-20210203","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(03)00010-X","article-title":"Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolaemic patients with peripheral vascular disease.","volume":"114","author":"Mondillo","year":"2003","journal-title":"Am J Med"},{"key":"R32-11-20210203","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomised trial.","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"R33-11-20210203","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/01.CIR.91.10.2528","article-title":"Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS).","volume":"91","author":"Jukema","year":"1995","journal-title":"Circulation"},{"key":"R34-11-20210203","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"key":"R35-11-20210203","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomised controlled trial.","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"R36-11-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Study.","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"R37-11-20210203","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID Trial.","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"R39-11-20210203","first-page":"40","article-title":"Glycaemic control of type 2 diabetic patients on follow-up at Hospital Universiti Sains Malaysia.","volume":"10","author":"Eid","year":"2003","journal-title":"Malaysian J Med Sci"},{"key":"R40-11-20210203","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"R41-11-20210203","first-page":"S1247","article-title":"Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.","volume":"6","author":"Nass","year":"2000","journal-title":"Am J Manag Care"},{"key":"R42-11-20210203","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1161\/01.ATV.0000090521.25968.4D","article-title":"Thiazolidinediones and blood lipids in type 2 diabetes.","volume":"23","author":"van Wijk","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R43-11-20210203","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"GLAI Study Investigators. A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidaemia.","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diab Care"},{"key":"R44-11-20210203","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update.","volume":"111","author":"Pepys","year":"2003","journal-title":"Clin Invest"},{"key":"R45-11-20210203","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation.","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"R46-11-20210203","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"R47-11-20210203","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/diacare.28.9.2206","article-title":"An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes.","volume":"28","author":"Williams","year":"2005","journal-title":"Diab Care"},{"key":"R48-11-20210203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1191\/1358863x05vm635oa","article-title":"The association between smoking and the prevalence of intermittent claudication.","volume":"10","author":"Jensen","year":"2005","journal-title":"Vasc Med"},{"key":"R49-11-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/153857440503900609","article-title":"Risk factors for poor collateral development in claudication.","volume":"39","author":"De Vivo","year":"2005","journal-title":"Vasc Endovascular Surg"},{"key":"R50-11-20210203","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1291\/hypres.28.631","article-title":"Smoking and antihypertensive medication: interaction between blood pressure reduction and arterial stiffness.","volume":"28","author":"Matsui","year":"2005","journal-title":"Hypertens Res"}],"container-title":["Blood Coagulation &amp; Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001721-201109000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:57:25Z","timestamp":1786039045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-201109000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e32834740ba","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}